Drug Delivery

Opiant's nasal opioid overdose drug clears PK test, edges closer to FDA filing

By Nick Paul Taylor

Opiant Pharmaceuticals has taken another step toward filing for approval of its nasal opioid overdose drug. With the pharmacokinetic study showing the drug is absorbed quickly in the nose, Opiant remains on track to submit an application to the FDA later this year.

read more

NIH-backed nasal nonaddictive pain prospect clears early test

By Nick Paul Taylor

Virpax Pharmaceuticals has brought its nasal spray for acute and chronic pain through an early test. With the NIH footing the bill, Virpax posted a clear toxicology report in a preclinical studies in preparation for filing to study the candidate in humans.

read more

The top 10 M&A targets in biotech for 2022

By Annalee Armstrong

All the biopharma world is talking about right now is M&A. Who’s going to buy? How much are they willing to spend? Who’s going to get bought? Here are our predictions.

read more

Whitepaper: The CNS Market: 2021 Year in Review & Outlook for 2022

Sponsored by: Blue Matter, strategic consultants in the life sciences

What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more.

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Sponsored by: Catalent Biologics

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Article: Formulation Strategies When Transitioning From Vial to PFS

Sponsored by: Catalent

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.